Alpha Tau Medical Ltd. - Ordinary Shares (NQ:DRTS)

6.550 -0.310 (-4.52%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2026 Add to My Watchlist

Price and Volume

Volume	243,492
Open	6.900
Bid (Size)	6.500 (100)
Ask (Size)	6.650 (1,100)
Prev. Close	6.860
Today's Range	6.351 - 6.979
52wk Range	2.300 - 8.600
Shares Outstanding	68,575,397
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

March 16, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

February 24, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Performance

YTD	+35.6%	+35.6%
1 Month	-15.6%	-15.6%
3 Month	+29.4%	+29.4%
6 Month	+54.1%	+54.1%
1 Year	+161.0%	+161.0%

More News

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

January 06, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

January 05, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

In today's session, these stocks are experiencing unusual volume. ↗

December 11, 2025

Via Chartmill

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

December 09, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium

December 04, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer

December 02, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 22, 2025

Via Benzinga

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

October 21, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

September 02, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Stock Rallies To 3-Month High On Smaller-Than-Feared Q1 Loss: Retail Sentiment Stays Bearish ↗

May 20, 2025

Via Stocktwits

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

April 28, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

April 02, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

March 18, 2025

Via ACCESS Newswire

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

February 24, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

February 03, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

January 27, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

December 18, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

December 17, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

October 21, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Treats First Patient with Recurrent Lung Cancer

October 10, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

September 20, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q2 2024 ↗

August 14, 2024

Via InvestorPlace

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

June 25, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Frequently Asked Questions

Is Alpha Tau Medical Ltd. - Ordinary Shares publicly traded?

Yes, Alpha Tau Medical Ltd. - Ordinary Shares is publicly traded.

What exchange does Alpha Tau Medical Ltd. - Ordinary Shares trade on?

Alpha Tau Medical Ltd. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Alpha Tau Medical Ltd. - Ordinary Shares?

The ticker symbol for Alpha Tau Medical Ltd. - Ordinary Shares is DRTS on the Nasdaq Stock Market

What is the current price of Alpha Tau Medical Ltd. - Ordinary Shares?

The current price of Alpha Tau Medical Ltd. - Ordinary Shares is 6.550

When was Alpha Tau Medical Ltd. - Ordinary Shares last traded?

The last trade of Alpha Tau Medical Ltd. - Ordinary Shares was at 03/30/26 04:00 PM ET

What is the market capitalization of Alpha Tau Medical Ltd. - Ordinary Shares?

The market capitalization of Alpha Tau Medical Ltd. - Ordinary Shares is 449.17M

How many shares of Alpha Tau Medical Ltd. - Ordinary Shares are outstanding?

Alpha Tau Medical Ltd. - Ordinary Shares has 449M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.